Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Twist Bioscience Corp’s stock clocked out at $48.43, up 1.96% from its previous closing price of $47.50. In other words, the price has increased by $1.96 from its previous closing price. On the day, 0.93 million shares were traded. TWST stock price reached its highest trading level at $49.75 during the session, while it also had its lowest trading level at $46.64.
Ratios:
To gain a deeper understanding of TWST’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.54 and its Current Ratio is at 4.88. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on December 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $60.
On June 04, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $53.
Goldman Upgraded its Neutral to Buy on January 17, 2024, whereas the target price for the stock was revised from $25 to $45.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 16 ’24 when Cho Dennis bought 133 shares for $46.81 per share.
Cho Dennis sold 367 shares of TWST for $19,342 on Dec 06 ’24. The insider now owns 113,620 shares after completing the transaction at $52.70 per share. On Dec 06 ’24, another insider, Green Paula, who serves as the SVP of Human Resources of the company, sold 860 shares for $52.70 each. As a result, the insider received 45,325 and left with 133,715 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TWST now has a Market Capitalization of 2874630400 and an Enterprise Value of 1958998016. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.21 while its Price-to-Book (P/B) ratio in mrq is 6.03. Its current Enterprise Value per Revenue stands at 6.636 whereas that against EBITDA is -12.504.
Stock Price History:
Over the past 52 weeks, TWST has reached a high of $60.90, while it has fallen to a 52-week low of $27.41. The 50-Day Moving Average of the stock is 7.78%, while the 200-Day Moving Average is calculated to be 11.23%.
Shares Statistics:
It appears that TWST traded 739.83K shares on average per day over the past three months and 766570 shares per day over the past ten days. A total of 58.88M shares are outstanding, with a floating share count of 56.15M. Insiders hold about 5.41% of the company’s shares, while institutions hold 110.20% stake in the company. Shares short for TWST as of 1730332800 were 9020037 with a Short Ratio of 13.04, compared to 1727654400 on 8701877. Therefore, it implies a Short% of Shares Outstanding of 9020037 and a Short% of Float of 20.1.
Earnings Estimates
A comprehensive evaluation of Twist Bioscience Corp (TWST) is underway, with the input of 2.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.61, with high estimates of -$0.59 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$2.25 and -$2.34 for the fiscal current year, implying an average EPS of -$2.3. EPS for the following year is -$1.84, with 3.0 analysts recommending between -$1.58 and -$2.1.
Revenue Estimates
In the current quarter, 9 analysts expect revenue to total $86.95M. It ranges from a high estimate of $87.1M to a low estimate of $86.77M. As of the current estimate, Twist Bioscience Corp’s year-ago sales were $71.5MFor the next quarter, 9 analysts are estimating revenue of $90.7M. There is a high estimate of $91.95M for the next quarter, whereas the lowest estimate is $89.3M.
A total of 11 analysts have provided revenue estimates for TWST’s current fiscal year. The highest revenue estimate was $376M, while the lowest revenue estimate was $370.6M, resulting in an average revenue estimate of $373.13M. In the same quarter a year ago, actual revenue was $312.97MBased on 11 analysts’ estimates, the company’s revenue will be $438.52M in the next fiscal year. The high estimate is $450.59M and the low estimate is $423.5M.
